SynthesisBMC cancer2025
Prognostic significance of miR-378 in cancers: a meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A powerful representation learning method for enhanced analysis of incomplete multi-omics data.NPJ systems biology and applications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic significance of miR-378 in cancers remains controversial. We carried out the meta-analysis to clarify the issue.
methodsRelated researches were obtained from PubMed, Web of Science and EMBASE. The search was conducted up until 10 September 2023. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to access the correlation between miR-378 and survival outcomes and clinicopathological features.
results16 articles were included in the meta-analysis. The pooled analysis showed that low miR-378 expression predicted poor overall survival (OS) (HR: 1.73, 95% CI: 1.09-2.74). No significant difference was discovered between low miR-378 expression and disease-free survival/ recurrence-free survival (DFS/RFS) (HR: 1.43; 95% CI: 0.79-2.59). Subgroup analysis revealed that the low miR-378 expression had better predictive value for CRC (HR: 2.97, 95% CI: 1.27-6.96), GC (HR: 2.12, 95% CI: 1.23-3.67) and glioma (HR: 3.87, 95% CI: 1.52-9.81). In addition, low miR-378 expression had positive correlation with lymph node metastasis (yes vs. no)(OR: 2.42, 95% CI: 1.55-2.87) and distant metastasis (yes vs. no) (OR: 1.26, 95% CI: 1.04-2.35).
conclusionMiR-378 could be an efficient prognostic biomarker in cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.